EICHOR
● Active Not Recruiting
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1
Condition: Hypertension · Overweight or Obesity · Sponsor: Eli Lilly and Company
About this study
GZL1 is an independent study conducted under the GZPL master protocol. GZL1 will evaluate the efficacy and safety of orforglipron for treatment of hypertension in participants with obesity or overweight.
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (99)
| Elite Clinical Studies, LLC | Phoenix, Arizona, United States | — |
| Valley Clinical Trials, Inc. | Covina, California, United States | — |
| Valley Clinical Trials, Inc. | Northridge, California, United States | — |
| Chase Medical Research, LLC | Waterbury, Connecticut, United States | — |
| Excel Medical Clinical Trials | Boca Raton, Florida, United States | — |
| Care Access - Brandon | Brandon, Florida, United States | — |
| Northeast Research Institute - Downtown Office | Jacksonville, Florida, United States | — |
| Peace River Cardiovascular Center | Port Charlotte, Florida, United States | — |
| East-West Medical Research Institute | Honolulu, Hawaii, United States | — |
| Ascension Saint Agnes Heart Care | Baltimore, Maryland, United States | — |
| Lucida Clinical Trials | New Bedford, Massachusetts, United States | — |
| Arcturus Healthcare , PLC, Troy Internal Medicine Research Division | Troy, Michigan, United States | — |
+ 87 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.